September 2024 DELEX Pharma International, Inc. has acquired JMN Brothers Pharma Limited, Inc. (JMN Pharma) in 2022. JMN Pharma was established in 2018 and known for its expertise in Women’s Health and Beauty, along with its ethical business in hospital products. The company is led by experienced executives from multinational pharmaceutical organizations. This strategic acquisition is projected to account for 20% of DELEX Pharma’s total corporate revenue, further strengthening its position in the over-the-counter (OTC) healthcare market.
According to Statista, the Beauty and Personal Care Market in the Philippines is projected to generate US$6.47 billion in revenue in 2024, with an annual growth rate of 0.76% from 2024 to 2028.
Thus, in response to the growing Beauty and Personal Care Market in the Philippines, DELEX, through JMN Pharma, has been marketing Multivitamins + Selenium (EC-VIT), a product tailored to the evolving health and beauty needs of Filipinos. In addition, EC-VIT includes the unique mineral Selenium, which, due to its potency, is poised to capture a significant share of the multivitamin market containing Zinc, through the ongoing comprehensive full-scale promotions and initiatives of DELEX Pharma.
JMN Pharmas Multivitamins + Selenium (EC-VIT) addresses not only beauty concerns but also contributes to overall health. With 71% of Filipinos expressing a desire to “stay healthy and avoid illnesses,” as reported by the Manila Bulletin in the first quarter of 2024, EC-VIT stands as an essential supplement in both beauty and health, offering benefits that extend to chronic disease prevention.
The Philippines continues to record a high live birth rate, measured at 19.378 births per 1,000 people in 2024. Recognizing the increasing demand for prenatal and postnatal supplements, JMN Pharma launched OBNate IQ Plus, specifically formulated for pregnant and lactating women.
Additionally, JMN Pharma markets Clotrimazole (Vagison) for the treatment of vaginal candidiasis, a condition prevalent during pregnancy. Healthline reports that Candida infections are more common during pregnancy, highlighting the importance of products like Vagison. It serves not only pregnant women but also the general female population, addressing approximately 80.40% of fungal infections among women in the Philippines.
At present, JMN Pharma supports the marketing needs of DELEX Pharma to compete with other brands in a wide range of accounts, such as tertiary and primary hospitals in both private and public sectors. In a strategic move, industry executives have strategically placed JMN, the distributor of DELEXs rival products, to provide hospitals with an alternative that allows them to stay within DELEX network, whereby minimizing the inclination to explore products from other competing brands. This approach aims to expands DELEs ethical business footprint in the healthcare market.
According to Statista, the hospitals market in the Philippines is expected to grow by 9.25% between 2024 and 2029, reaching a market volume of US$7.9 billion. Whereas, continuously permeating the ethical market allows DELEX Pharma to contribute significantly to this growth, further fortifying its mission to providing high-quality healthcare solutions.
BNCM is an Asset Management Company that secures its assets by investing in companies with strong growth potentials, robust revenues, significant profits, proven track records, and promising business models with highly experienced management teams that will exceptionally qualify for quotation and listing on the OTC or NASDAQ markets within the next 2 to 3 years. The growth of these companies will directly provide more employment opportunities to the communities, improve the country’s economy, and bring greater social change.
For more information, visit: https://www.bncm.net/
DELEX is a Delaware-registered company, and the holding company of DLX Holdings, Inc. (DLX). DLX is a Philippine-based parent company that holds a 60% controlling interest in Delex Pharma International, Inc. an ISO 9001-2015 Certified company, which also holds a controlling interest in JMN Brother’s Pharma Limited, Inc. DLX and its subsidiaries are involved in the development and distribution of pharmaceutical and healthcare products in the Philippines.
For more information, visit: https://delexhealth.com
